Acute liver failure

This early-stage trial tested a device called miroliverELAP, which uses a bioengineered liver graft to filter blood outside the body, in 10 adults with acute liver failure. The goal was to check safety and see if it can support the liver for up to 48 hours, giving time for recove…

This study compares two machines that clean the blood of toxins when the liver fails: MARS (a standard system) and SPAD (a simpler, cheaper alternative). Thirty-four patients with severe liver failure will try both machines in random order. The goal is to see if SPAD works as wel…

This study investigates how a single dose of mavorixafor is processed in people with mild to moderate liver impairment compared to healthy volunteers with normal liver function. Researchers will measure drug levels in the blood and monitor safety and tolerability. The goal is to …

This study looked at how the body handles a drug called BI 1584862 in people with different levels of liver function. 43 adults with mild, moderate, or severe liver problems, plus a group with healthy livers, took a single dose of the drug. Researchers measured drug levels in the…

This study looked back at the medical records of 27 patients with alcoholic hepatitis or sudden liver failure who received a treatment called MARS (a type of dialysis that cleans the blood). The goal was to see if MARS helped them survive without needing a liver transplant. Resea…

This study looked at how the experimental drug iclepertin (BI 425809) is processed in people with and without liver problems. 29 adults aged 18-79 took a single dose of the drug. Researchers measured drug levels in the blood and monitored safety to see if liver impairment changes…

This pilot study looked at 38 liver transplant patients to see if liver failure lowers blood levels of pyrophosphate, a natural substance that prevents calcium buildup in tissues. Researchers measured pyrophosphate before and after transplant and checked liver tissue for a relate…

This study looks at how the drug BI 1015550 is absorbed and processed in the blood of people with mild or moderate liver problems compared to those with healthy livers. About 28 adults took a single dose and had blood samples taken over several days. The goal is to understand if …

This completed Phase 1 study looked at how imlunestrant, an oral drug, enters the bloodstream and leaves the body in women with and without liver impairment. 27 female participants took a single dose, and researchers measured drug levels over time. The goal is to understand if li…